

Pr **DOJOLVI**[®]

Triheptanoin Oral Liquid

NEWFOUNDLAND AND LABRADOR

Ultragenyx Canada would like to announce that PrDOJOLVI[®] (triheptanoin) is eligible for public reimbursement in Newfoundland and Labrador for patients with LC-FAOD based on the reimbursement criteria detailed below under the Newfoundland and Labrador Prescription Drug Program (NLPDP).

DOJOLVI[®] (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi_Final_PM.pdf for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

The DOJOLVI[®] Reimbursement Criteria for the [Newfoundland and Labrador Prescription Drug Program](#) Are as Follows:

Benefit List:

Special Authorization: New Addition: DOJOLVI 100% w/w oral liquid

TRihePTANOIN (DOJOLVI 100% w/w oral liquid)

For the treatment of adult and pediatric patients with an acute life-threatening long-chain fatty acid oxidation disorder (LC-FAOD) as a source of calories and fatty acids only if the following conditions are met:

- Patients with a confirmed diagnosis of LC-FAOD and acute life-threatening events who require alternative therapy to conventional even-chain medium-chain triglyceride (MCT) supplementation or
- Patients without a confirmed diagnosis of LC-FAOD presenting with acute life-threatening events consistent with LC-FAOD who require alternative therapy to conventional even-chain MCT supplementation

Clinical Notes

- Patients should be under the care of a specialist with expertise in the diagnosis and management of LC-FAOD.
- Approval period: 1 year. Confirmation of continued response is required for renewal.

For more information on applying for DOJOLVI[®] coverage, we can arrange an appointment at your convenience, or you can visit the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.

MRCP-UX007-00812
01/2024

ultragenyx